This Method is drafted by China's National Medical Products
Administration in conjunction with the China National IP
Administration, and was published for public's comments on 11
September 2020 in the link below. The deadline to provide comments
is 25 October 2020.
The draft Method has 15 articles.
https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20200911175627186.html
Please refer to my summary below:
- The drug originator is required to register patent information
related to the drug at the NMPA in order to enjoy protection.
(Article 2).
- The drug originator could update patent information, within 30
days from any change (patent granted, change of patentee, and so
on) happened. (Articles 3 and 4).
